ArticleBriefings in bioinformatics2026
Integrating multi-structure covalent docking with machine-learning consensus scoring enhances potency ranking of human acetylcholinesterase inhibitors.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The covalent docking software landscape: features and applications in drug design.Briefings in bioinformatics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Acetylcholinesterase (AChE) inhibition is a key mechanism in the treatment of neurodegenerative diseases and in counteracting toxic exposures to pesticides and nerve agents. However, accurately ranking the potency of covalently binding AChE inhibitors remains challenging due to the enzyme's structural flexibility and the chemical diversity of their covalent warheads. In this study, we developed an in silico protocol that integrates multi-structure covalent docking and machine-learning (ML) consensus scoring to improve docking-based potency ranking among covalent AChE inhibitors. We analyzed 65 ligand-bound (holo) human AChE crystal structures using hierarchical clustering to identify four representative conformations, along with one high-resolution apo structure, for multi-structure docking. A curated library of 412 organophosphate and carbamate inhibitors was then docked covalently and non-covalently into each receptor conformation. The resulting docking scores were evaluated against inhibitors' experimental logIC50 values using Spearman's rank correlation coefficient (rs). Covalent docking outperformed non-covalent docking (rs values up to 0.54 versus 0.18), and our ML consensus model trained on the five structures' covalent docking scores achieved the highest predictive accuracy (rs = 0.70), surpassing all single-structure and heuristic consensus baselines. Chemical cluster analysis revealed structure-activity trends based on ligand flexibility, polarity, and aromaticity. SHapley Additive exPlanations analysis highlighted the ML consensus model's ability to flexibly distribute the influence each structure's scores played on its predictions. It identified and exploited relationships based on its training dataset that would be difficult to anticipate through a manual analysis of individual structures' docking performance metrics. This framework is broadly applicable to other covalently targeted proteins, offering a generalizable and interpretable strategy for docking-based potency ranking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.